ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

Amrita Goyal, Daniel O'Leary, Bouthaina Dabaja, Wen Kai Weng, Jasmine Zain, Corey Cutler, Joan Guitart, Youn H. Kim, Larisa J. Geskin, Richard T. Hoppe, Lynn D. Wilson, Anne W. Beaven, Steve Horwitz, Pamela B. Allen, Stefan K. Barta, Kimberly Bohjanen, Jonathan E. Brammer, Joi B. Carter, Nneka Comfere, Jennifer A. DeSimoneKathryn Dusenbery, Madeleine Duvic, Auris Huen, Deepa Jagadeesh, Chris R. Kelsey, Michael S. Khodadoust, Mary Jo Lechowicz, Neha Mehta-Shah, Alison J. Moskowitz, Elise A. Olsen, Christina Poh, Barbara Pro, Christiane Querfeld, Craig Sauter, Lubomir Sokol, Olayemi Sokumbi, Ryan A. Wilcox, John A. Zic, Mehdi Hamadani, Francine Foss

Research output: Contribution to journalArticlepeer-review

Abstract

Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience progressive and/or treatment-refractory disease; Sézary syndrome is an aggressive lymphoma associated with high morbidity and mortality. Although allogeneic hematopoietic cell transplant (allo-HCT) is the only currently available potentially curative treatment modality for MF/SS there is no published guidance on referral criteria, transplant timing orallo-HCT approach. To develop consensus clinical practice recommendations, we performed a Delphi survey of 32 specialists in dermatology (n = 9), transplant hematology/oncology (n = 10), non-transplant hematology/oncology (n = 8), and radiation oncology (n = 5) from across the United States. Consensus required agreement of ≥75% of participants. Sixteen consensus statements were generated on four topics: (1) criteria for referral for consideration for allo-HCT, (2) allo-HCT preparative regimens and procedures (3) disease status at the time of allo-HCT, and (4) multidisciplinary management in the pre- and post-transplant settings. These clinical practice guidelines provide a framework for decision-making regarding allo-HCT for MF/SS and highlight areas for future prospective investigation.

Original languageEnglish
Pages (from-to)1047-1060
Number of pages14
JournalTransplantation and Cellular Therapy
Volume30
Issue number11
DOIs
StatePublished - Nov 2024

Fingerprint

Dive into the research topics of 'ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome'. Together they form a unique fingerprint.

Cite this